Navigation Links
Genetics Determine Optimal Drug Dose of Common Anticoagulant
Date:8/21/2007

WASHINGTON, Aug. 21 /PRNewswire-USNewswire/ -- Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology. This result represents one of the first applications of using an individual's genetic information to guide personal medical care.

Because individuals metabolize drugs differently, varying doses of warfarin are needed for the drug to be effective in each patient. Too much warfarin can cause severe bleeding, and too little can cause dangerous blood clots. Currently, there is little guidance for predicting how much of the drug a person will need. Physicians have had to roughly estimate an initial dose of warfarin and then continually monitor a patient's International Normalized Ratio (INR) value (a measure of how fast the blood clots), during treatment to tweak the dosage by trial and error.

For the first time, a group of St. Louis researchers combined the standard INR method with genetic testing to predict the therapeutic warfarin dose. Since warfarin is often prescribed after major orthopedic surgery to prevent blood clots in the legs, the study followed 92 adults undergoing either total hip or knee replacement at the Washington University Medical Center, who had never previously taken the anticoagulant.

Prior to warfarin treatment, the researchers collected blood samples and each patient's medical history. The blood tests were used to examine variations in two genes, CYP2C9 and VKORC1, that may affect warfarin dosing. Variants in CYP2C9 impair the body's breakdown of warfarin; variants in VKORC1 cause increased warfarin sensitivity. The patients were assigned initial doses of warfarin based on clinical factors and their genotype. The researchers followed the patients until successful treatment outcomes were achieved several weeks later.

By combining
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, Inc. ... in bioactive lipid-targeted therapeutics, received official notification from the ... granted another key patent supporting its iSONEP™ and ... patent, European patent No. 2087002, claims compositions of ... Lpath,s two lead compounds, iSONEP and ASONEP. Sonepcizumab ...
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... April 12, 2011 Visual Healthcare Corp. (the "Company") (NASDAQ ... Chinese based adaptation of the information technology grid that its ... This project has been launched in response to requests from ... experts responding to Chinese government resolve to create a major ...
... 2011 Southern Home Medical Equipment, Inc. (PINKSHEETS: ... professionals and equipment to medical institutions, announced today ... for fiscal year 2010 have been restated to ... Staffing. In a previous announcement dated ...
Cached Medicine Technology:Visual Healthcare to Support Chinese Clinical Trials 2Visual Healthcare to Support Chinese Clinical Trials 3Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2
(Date:10/20/2014)... October 20, 2014 Houston plastic surgeon ... the key elements of his innovative True Form ... plastic surgery residents and faculty at The University ... he, too, was once a medical student. Patronella, who ... private cosmetic plastic surgery practices in Texas, The ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... 2014 Recently, BambooIndustry.com, one of the ... new range of bamboo deckings . Moreover, the ... items; they are now available at deeply discounted rates. ... is hard to overstate the significance of online business ... online services. The company’s workers are striving to deliver ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... 20, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, GoDaddy and HostMonster are the best ... (Virtual Private Server) is the method of partitioning ... of which has the appearance and capabilities of ... why the site pays close attention to VPS ...
Breaking Medicine News(10 mins):Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... 12 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... of Suzanne D. Snapper to succeed soon-to-be-retiring CFO ... , Ms. Snapper has been serving as ...
... MedApps, Enabling Mobile Wireless Technology Links Patients, Care ... Retail Off-the-Shelf Medical DevicesSCOTTSDALE, Ariz., May 12 ... provide a new, convenient and cost effective solution ... health record. MedApps, HealthPAL is a unique solution ...
... Carbon Footprint at DaVita,s Six Corporate Business OfficesEL SEGUNDO, ... DVA ), a leading provider of kidney care services ... announced that the company is the first FORTUNE 500 ... (EPA) Green Power Partnership program. Joining this program is ...
... 12 Occlutech, the leading European,developer of septum occluders, today ... generation ASD and PFO occluders, the Figulla Flex. , ... encompass a new innovative,delivery system, making the use of a ... the ability of the delivery,system to allow a 45 degree ...
... will present technology and admissions educational sessions for ACHCA members ... ... 12, 2009 --Patient Placement Systems, the leading provider of automated ... will exhibit and present two sessions at the American College ...
... love its usability & CCHIT recognizes its functionality; CureMD EHR ... ... New York, NY (PRWEB) May 12, 2009 -- The Certification ... EHR v10 complies with updated interoperability requirements, is a conditionally ...
Cached Medicine News:Health News:The Ensign Group Announces the Retirement of CFO Alan J. Norman; Names Suzanne D. Snapper as New Chief Financial Officer 2Health News:MedApps HealthPAL Connects to Microsoft HealthVault to Improve Patient Compliance and Lower Healthcare Costs 2Health News:MedApps HealthPAL Connects to Microsoft HealthVault to Improve Patient Compliance and Lower Healthcare Costs 3Health News:DaVita Becomes the First FORTUNE 500 Healthcare Services Company to Join the EPA Green Power Partnership 2Health News:DaVita Becomes the First FORTUNE 500 Healthcare Services Company to Join the EPA Green Power Partnership 3Health News:Patient Placement Systems Presenting Two Sessions at ACHCA 2009 Convocation 2Health News:Patient Placement Systems Presenting Two Sessions at ACHCA 2009 Convocation 3Health News:Doctors Love its Usability & CCHIT Recognizes its Functionality; CureMD EHR v10 CCHIT 08 Certified 2Health News:Doctors Love its Usability & CCHIT Recognizes its Functionality; CureMD EHR v10 CCHIT 08 Certified 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: